van Kampen Sanne Christine, Tursynbayeva Aigul, Koptleuova Aliya, Murzakhmetova Zauresh, Bigalieva Lyazzat, Aubakirova Moldir, Pak Svetlana, van den Hof Susan
KNCV Tuberculosis Foundation, Central Office, The Hague, Netherlands.
KNCV Tuberculosis Foundation, Central Asia Office, Almaty, Kazakhstan.
PLoS One. 2015 Jul 16;10(7):e0132514. doi: 10.1371/journal.pone.0132514. eCollection 2015.
Xpert MTB/RIF (Xpert) was piloted in Kazakhstan to detect tuberculosis (TB) and rifampicin resistance (RR-)TB among individuals at risk of multidrug-resistant (MDR-) TB. This study assessed the performance of Xpert compared to conventional diagnostic methods, RR-TB case detection among various risk groups, treatment initiation and time to diagnosis and treatment.
Eligible individuals were tested with Xpert, smear microscopy, culture and drug-susceptibility testing (DST) at the national TB reference laboratory and three provincial laboratories. Data was collected prospectively from August 2012 to May 2013 from routine laboratory and treatment registers.
A total of 5,611 Xpert tests were performed mostly targeting contacts of MDR-TB patients, 'other' presumptive MDR-TB patients, and retreatment cases (26%, 24% and 22%, respectively). Compared to phenotypic DST, the positive predictive value of Xpert to detect RR-TB was 93.1% and 96.4% and the negative predictive value was 94.6% and 92.7% using solid and liquid culture media, respectively. RR-TB detection was highest among (former) prisoners, retreatment cases, people living with HIV/AIDS (PLWHA), and TB patients with positive smears after intensive phase of treatment (59%, 58%, 54% and 53% among TB positives, respectively). 88.9% of RR-TB patients were registered to have started second-line TB treatment. Median time to diagnosis with Xpert was 0.0 days (IQR 0.0-1.0), time from diagnosis to start of first-line treatment 3.0 days (IQR 1.0-7.0), and to start of second-line treatment 7.0 days (IQR 4.0-16).
Compared to conventional culture and DST, Xpert had a shorter result turn-around-time and excellent concordance to detect RR-TB. Time from sputum collection to start of second-line treatment was reduced to one week. The yield of Xpert could be maximized by increasing referrals from penitentiary and HIV centers to TB centers.
在哈萨克斯坦开展了Xpert MTB/RIF(Xpert)检测,以在耐多药结核病(MDR-TB)风险个体中检测结核病(TB)和利福平耐药结核病(RR-TB)。本研究评估了Xpert与传统诊断方法相比的性能、不同风险组中RR-TB病例的检出情况、治疗启动以及诊断和治疗时间。
符合条件的个体在国家结核病参考实验室和三个省级实验室接受Xpert、涂片显微镜检查、培养及药敏试验(DST)检测。2012年8月至2013年5月从常规实验室和治疗登记册中前瞻性收集数据。
共进行了5611次Xpert检测,主要针对MDR-TB患者的接触者、“其他”疑似MDR-TB患者和复治病例(分别占26%、24%和22%)。与表型DST相比,使用固体和液体培养基时,Xpert检测RR-TB的阳性预测值分别为93.1%和96.4%,阴性预测值分别为94.6%和92.7%。RR-TB检出率在( former)囚犯、复治病例、艾滋病毒/艾滋病感染者(PLWHA)以及强化期治疗后涂片阳性的TB患者中最高(TB阳性者中分别为59%、58%、54%和53%)。88.9%的RR-TB患者登记开始二线抗结核治疗。Xpert诊断的中位时间为0.0天(四分位间距0.0 - 1.0),从诊断到开始一线治疗的时间为3.0天(四分位间距1.0 - 7.0),到开始二线治疗的时间为7.0天(四分位间距4.0 - 16)。
与传统培养和DST相比,Xpert检测RR-TB的结果周转时间更短且一致性良好。从痰液采集到开始二线治疗的时间缩短至一周。通过增加从监狱和艾滋病毒中心转介至结核病中心的病例数,可使Xpert的检出率最大化。